Alfonsus M. Van Den Eertwegh

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 03, 2024

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 12, 2024

Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 25, 2024

A prediction model for response to immune checkpoint inhibition in advanced melanoma.

A prediction model for response to immune checkpoint inhibition in advanced melanoma.

Journal: International journal of cancer

Published: July 05, 2023

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 24, 2023

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.

Journal: Cancers

Published: March 20, 2023

Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.

Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.

Journal: International journal of cancer

Published: January 02, 2023

Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.

Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.

Journal: European urology

Published: December 14, 2022

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.

Journal: Cancers

Published: November 01, 2022

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.

Journal: NEJM evidence

Published: November 01, 2022

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.

Journal: JAMA oncology

Published: October 27, 2022

Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry.

Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry.

Journal: Cancers

Published: October 18, 2022

Showing 1-12 of 43

Last Updated: 09/26/2026